Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORY-2001 phase 2 study in relapsing-remitting and secondary progressive multiple sclerosis
2017-002838-23Phase 2Completed
- Sponsor
- Oryzon Genomics
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vafidemstat in multiple sclerosis (MS) and secondary-progressive multiple sclerosis (SPMS) (3 arms), sponsored by Oryzon Genomics. Primary endpoint: Number, frequency and severity of adverse events. Started Jul 2017; status: completed.
02
Drugs
vafidemstat
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2017-002838-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002838-23.